CAR-T & Cellular Therapy
Myeloma highlights at EHA 2023: CARTITUDE-4 & CARTITUDE-1 updates & the use of MRD in clinical practice
In recent years, CAR-T cell therapy has transformed the myeloma treatment landscape and has provided a valuable option to patients…
Date: 22nd June 2023
Lymphoma highlights at EHA 2023: sequencing bispecifics & CAR-T cells, bridging therapy & toxicity management
The treatment landscape of large B-cell lymphoma (LBCL) has transformed in recent years, with novel immunotherapies including bispecific antibodies and…
Date: 16th June 2023
iwCAR-T Session IV: CAR-T therapy in CLL: challenges, combination approaches and ongoing trials
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Date: 7th June 2023
iwCAR-T Session III: CAR-T therapy in AML: ongoing challenges and strategies to improve patient outcomes
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Date: 24th May 2023
iwCAR-T Session II: CAR-T therapy in ALL: ongoing challenges and future outlooks
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Date: 18th May 2023
iwCAR-T Session I: CAR-T therapy in lymphoma and the role of bispecific antibodies
The 5th International Workshop on CAR-T (iwCAR-T) took place in Scottsdale, AZ, on 14 – 16 April, 2023, and brought…
Date: 11th May 2023
iwMyeloma Session III: reaching a cure for multiple myeloma and concepts that need to be addressed
The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and…
Date: 2nd May 2023
iwMyeloma Session II: the tumor microenvironment and mechanisms of resistance to targeted therapies
The 16th International Workshop on Multiple Myeloma (iwMyeloma) 2023 took place in Madrid, Spain, and brought together leading clinicians and…
Date: 19th April 2023
Insights into the changing role of chemotherapy in lymphoma
Although several novel agents have been implemented in the treatment of Hodgkin and non-Hodgkin lymphoma (HL; NHL), chemotherapy remains the…
Date: 31st March 2023
Managing and treating toxicities associated with CAR-T therapy: CRS, ICANS & infections
CAR-T cell therapy represents a major breakthrough in the treatment of hematological malignancies, including multiple myeloma, non-Hodgkin lymphoma (NHL), and…
Date: 16th March 2023
The growing role of immunotherapy in the treatment of ALL & moving away from stem cell transplantation
Over the years, the treatment landscape of B-cell acute lymphoblastic leukemia (B-ALL) has transformed with the implementation of novel immunotherapies,…
Date: 10th March 2023
The current status of CAR-T therapy in CLL and challenges in this space
In recent years, novel immunotherapies, including CAR-T cell therapy, have greatly improved treatment options for patients with hematological malignancies. Although CAR-T…
Date: 3rd March 2023